scholarly journals 498 Improving Surgical and Non-Surgical Oncological Outcomes in Patients with Head and Neck Cancer

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
B Atkinson ◽  
J Wilson
Keyword(s):  
Dna Repair ◽  
Head And Neck Cancer ◽  
Side Effects ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Cell Line ◽  
Mild Hyperthermia ◽  
Squamous Cells ◽  
Intensity Score ◽  
Dna Repair Protein

Abstract Introduction Treatment of head and neck cancer is complex and involves a multi-disciplinary approach between surgeons and oncologists. Radiotherapy often leaves patients with debilitating side effects such as mucositis, sialadenitis and dysphagia. Radiation induces double strand breaks (DSBs) in DNA within both normal squamous cells and squamous cell carcinomas (SCCs) that, if left unrepaired, initiates programmed cell death. Like normal squamous cells, SCC’s have an effective DNA repair pathway to protect against apoptosis by repairing DSBs through proteins such as FanD2-S331. This study aims to show that mild hyperthermia inhibits FancD2, therefore having the potential to increase the susceptibility of SCCs to radiotherapy and subsequently reducing the side effects. Method Head and neck cancer cell line UMSCC47 was cultured, then irradiated with 2 Gray before washing with an anti γH2AX antibody, used as a biomarker for DSBs. Fluorescent antibodies against FacD2-S331 were then used to assess the levels present within the nucleus of cells exposed to mild hyperthermia (39 °C) and then compared to untreated cells and cells exposed to radiation only. Results A γH2AX fluorophore intensity score of 58 following radiation compared to 20 in the control confirmed the presence of DSBs. A FancD2-s331 fluorophore intensity score of 76 was observed in cells exposed radiation. Cells exposed to heat prior to radiation showed a FancD2-s331 fluorophore score of 21. Conclusions Exposure of SCCs to mild hyperthermia before radiotherapy reduces activation of DNA repair protein FancD2-S2331. A reduction in DNA repair increases the susceptibility of SCCs to radiotherapy and apoptosis.

DNA Damage and Repair of Head and Neck Cancer Cells after Radio- and Chemotherapy

2009 ◽  
Vol 64 (7-8) ◽  
pp. 601-610 ◽  
Author(s):  
Pawel Rusin ◽  
Anna Walczak ◽  
Anita Zwierzchlejska ◽  
Jurek Olszewski ◽  
Alina Morawiec-Bajda ◽  
...  
Keyword(s):  
Dna Damage ◽  
Dna Repair ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Cells ◽  
Neck Cancer ◽  
Cancer Cell Line ◽  
Repair Capacity ◽  
Dna Damage And Repair ◽  
Γ Radiation

DNA repair is critical for successful chemo- and radiotherapy of human tumours, because their genotoxic sensitivity may vary in different types of cancer cells. In this study we have compared DNA damage and the efficiency of its repair after genotoxic treatment with hydrogen peroxide, cisplatin and γ-radiation of head and neck squamous cell carcinoma (HNSCC). Lymphocytes and tissue cells from biopsies of 37 cancer patients and 35 healthy donors as well as the HTB-43 larynx cancer cell line were employed. The cell sensitivity to genotoxic treatment was estimated by the MTT survival assay. The extent of DNA damage and efficiency of its repair was examined by the alkaline comet assay. Among the examined treatments, we found that HNSCC cells were the most sensitive to γ-radiation and displayed impaired DNA repair. In particular, DNA damage was repaired less effectively in cells from HNSCC metastasis than healthy controls. In conclusion, our results suggest that the different genotoxic sensitivity of HNSCC cells may depend on their DNA repair capacity what in turn may be connected with the effectiveness of head and neck cancer therapy.

scholarly journals DNA Repair in Lymphoblastoid Cell Lines From Patients With Head and Neck Cancer

1999 ◽  
Vol 125 (2) ◽  
pp. 185 ◽  
Author(s):  
Erich M. Sturgis ◽  
Gary L. Clayman ◽  
Yongli Guan ◽  
Zhaozheng Guo ◽  
Qingyi Wei
Keyword(s):  
Dna Repair ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cell Lines ◽  
Neck Cancer ◽  
Lymphoblastoid Cell Lines

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects

1995 ◽  
Vol 35 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Walter Van den Bogaert ◽  
Emmanuel van der Schueren ◽  
Jean-Claude Horiot ◽  
Mario De Vilhena ◽  
Simon Schraub ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Side Effects ◽  
Randomized Trial ◽  
Head And Neck ◽  
Neck Cancer ◽  
Long Term Results ◽  
Advanced Head

scholarly journals Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives

Nanomaterials ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 1938
Author(s):  
Jefferson Muniz de Lima ◽  
Paulo Rogerio Bonan ◽  
Danyel Elias da Cruz Perez ◽  
Michael Hier ◽  
Moulay A. Alaoui-Jamali ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Side Effects ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Basic Research ◽  
Cochrane Central Register ◽  
Level Of Evidence ◽  
Mortality And Morbidity

Head and neck cancer (HNC) is a complex and heterogeneous disease associated with high mortality and morbidity worldwide. Standard therapeutic management of advanced HNC, which is based on radiotherapy often combined with chemotherapy, has been hampered by severe long-term side effects. To overcome these side effects, tumor-selective nanoparticles have been exploited as a potential drug delivery system to improve HNC therapy. A combination of MEDLINE, EMBASE, Cochrane Oral Health Group’s Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov from inception up to June 2020 was used for this systematic review. A total of 1747 published manuscripts were reviewed and nine relevant references were retrieved for analysis, while eight of them were eligible for meta-analysis. Based on these studies, the level of evidence about the efficacy of nanoformulation for HNC therapy on tumor response and adverse side effects (SAE) was low. Even though basic research studies have revealed a greater promise of nanomaterial to improve the outcome of cancer therapy, none of them were translated into clinical benefits for HNC patients. This systematic review summarized and discussed the recent progress in the development of targeted nanoparticle approaches for HNC management, and open-up new avenues for future perspectives.

DNA repair gene polymorphisms and risk of head and neck cancer in the Tunisian population

2013 ◽  
Vol 43 (3) ◽  
pp. 217-224 ◽  
Author(s):  
Rim Khlifi ◽  
Imen Kallel ◽  
Bouthaina Hammami ◽  
Amel Hamza-Chaffai ◽  
Ahmed Rebai
Keyword(s):  
Dna Repair ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Gene Polymorphisms ◽  
Tunisian Population ◽  
Repair Gene ◽  
Dna Repair Gene

Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6077-6077 ◽  
Author(s):  
J. Buentzel ◽  
A. de Vries ◽  
O. Micke
Keyword(s):  
Head And Neck Cancer ◽  
Side Effects ◽  
Head And Neck ◽  
Neck Cancer ◽  
Egf Receptor ◽  
Therapeutic Option ◽  
Therapeutic Benefit ◽  
Platinum Resistance ◽  
Platinum Resistant ◽  
Recurrent Head

6077 Background: In patients with platinum-resistant recurrent head and neck cancer the Anti-EGF-receptor antibody cetuximab could be used as a treatment option. Little is known about results of this therapeutic option. The objective of this study was to evaluate therapeutic benefit of this indication. Methods: 23 patients with histological confirmed recurrent head and neck cancer (18 male, 3 female, median age was 57 years) were included in this exploratory study. All recurrences had occurred after chemotherapy with platinum- derivates. 19 patients received radiation therapy during primary treatment. No surgical or radiotherapeutic option in recurrent disease was possible. Two patients were diagnosed with lung metastasis. The 2nd-line therapy consisted of carboplatinum (200 mg/m2) + paclitaxel (200 mg/m2) every three weeks (week 1, 4, and 7) and additionally cetuximab, which was given with 400 mg/m2 as loading dose in week 1 and 250 mg/m2 in week 2–6. Results: A significant tumor response was observed in 13/23 patients (56%). 7 partial, 5 minor and one complete remission were registered. The median survival time was 8 month (range 3–10), 4 patients are still alive. Median time to progression was 5 month (range 2–8). Side effects were rash (16/22), fever (9/22) and typical chemotherapy induced toxicities as neuropathy (7/22) and cytopenia (4/22). All side effects were moderate and easy to handle. Conclusions: The described combined chemoimmuntherapy with cetuximab and paclitaxel + carboplatinum seems to offer new strategies in 2nd and 3rd line chemotherapy for patients with platinum-resistant head and neck cancer, potentially overcoming primary platinum resistance. No significant financial relationships to disclose.

DNA repair- and apoptosis-pathways to regulate response to chemo-radiotherapy (CRT) in patients (p) with locally advanced head and neck cancer (HNC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17025-e17025
Author(s):  
Beatriz Cirauqui ◽  
Vanesa Quiroga ◽  
Imane Chaib ◽  
Belen Sanchez ◽  
Niki Karachaliou ◽  
...  
Keyword(s):  
Dna Repair ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Apoptosis Pathways
Sign in / Sign up

Export Citation Format

Share Document